Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Multiple Myeloma
Updated Results from CARTITUDE-2 Trial of Ciltacabtagene Autoleucel in Lenalidomide-Refractory Patients with Progressive MM After 1 to 3 Previous Lines of Therapy
Read More
Results of the Phase 3 GMMG-HD7 Trial of Isatuximab plus Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy for Transplant-Eligible NDMM
Read More
International Myeloma Working Group Recommendations for the Treatment of Patients with RRMM
Read More
Longer-Term Outcomes with Single-Agent Belantamab Mafodotin in Patients with RRMM: 13-Month Follow-Up from the Pivotal DREAMM-2 Study
Read More
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd), Autologous Transplantation, and MRD Response–Adapted Treatment Modification in NDMM
Read More
Updated Results from the CARTITUDE-1 Study of Ciltacabtagene Autoleucel CAR T-Cell Therapy in RRMM
Read More
Updated Analysis of the GRIFFIN Trial of Daratumumab plus RVd in Transplant-Eligible NDMM
Read More
Meeting Highlights
New CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
Read More
Abecma First CAR T-Cell Therapy Approved for Multiple Myeloma
Read More
2
3
4
5
6
7
8
Page 5 of 10
Results 41 - 50 of 98